Magnevist and Nephrogenic Systemic Fibrosis

Send to Friend | Bookmark | Live Chat

The first cases of Nephrogenic Systemic Fibrosis were discovered in 1997 with the first medical references detailing the condition written in 2000. The condition only affects individuals with impaired renal function or renal failure and causes the skin and connective tissues in the body to thicken and harden. The typical symptoms of Nephrogenic Systemic Fibrosis include darkened patches appearing on the skin, a severe itching or burning sensation beneath the skin, skin becoming so tight that it begins to restrict movement. The condition affects males and females equally and can be found in individuals of every age, from children to seniors. Nephrogenic Systemic Fibrosis is a progressive condition and can ultimately prove to be fatal.

There is no known cure available for Nephrogenic Systemic Fibrosis and current treatments are often ineffective. The only option that has a consistent effect on the progression of the condition seems to be the improvement of renal function, which has been shown to halt the progression of the condition and in rare cases, began to reverse the damage done by the disorder. The exact reason for the development of Nephrogenic Systemic Fibrosis in some individuals remains unknown, the agents suspected of causing the development of the condition include surgery, vascular injury, and exposure to Gadolinium based contrast agents.

In 2006, the FDA issued two public health advisories warning healthcare professionals and patients with impaired renal function about the increased risk of developing Nephrogenic Systemic Fibrosis when exposed to a Gadolinium based contrast agent such as Magnevist. In all of the cases of Nephrogenic Systemic Fibrosis that the FDA had investigated, every individual had received an injection of a Gadolinium based contrast agent prior to an MRI procedure in the 2 days to 18 months before the onset of the condition. Although only three of the five approved Gadolinium based contrast agents were conclusively linked to these patients developing Nephrogenic Systemic Fibrosis, the FDA believes that the increased risk applies to all of the approved Gadolinium based contrast agents.

The manufacturer of Magnevist, Bayer Healthcare Pharmaceuticals, reports that they are cooperating fully with the US Food and Drug Administration and health authorities investigating the issue. Reports have been received linking the development of Nephrogenic Systemic Fibrosis to an injection of Magnevist, but those cases are still under review. Out of the 78 reports received by the manufacturer claiming an association between Magnevist and the development of Nephrogenic Systemic Fibrosis, 27 of the cases have been deemed plausible, 5 of the cases have been deemed unlikely, and 46 of the cases need more information to draw a conclusion. To date, Magnevist has been used in more than 80 million applications throughout the world and is available for use in more than 100 countries.

Main Gadolinium Content Sections

Gadolinium

Nephrogenic Systemic Fibrosis (NSF)

Nephrogenic Fibrosing Dermopathy (NFD)

Related Contents - Gadolinium, Nephrogenic Systemic Fibrosis / Nephrogenic Fibrosing Dermopathy

What Is Gadolinium?

Gadolinium and Magnetic Resonance Imaging (MRI)

Gadolinium and MRI Safety Guidelines

Gadolinium Side Effects and Complications

Issues with MRI Contrast Agents

Gadolinium Based Contrast Agents Used With Magnetic Resonance Imaging

Gadolinium and NSF/NFD

What Is Nephrogenic Systemic Fibrosis / Nephrogenic Fibrosing Dermopathy?

Does Gadolinium Based Contrast Agents Cause Nephrogenic Systemic Fibrosis?

Nephrogenic Systemic Fibrosis Associated With Agents Containing Gadolinium

Devastating Condition Called Nephrogenic Systemic Fibrosis Subject Of Alert By The FDA

The Theory Behind How Gadolinium Based Contrast Agents Cause Nephrogenic Systemic Fibrosis

Nephrogenic Systemic Fibrosis and MRI Contrast Agents

Symptoms and Signs of Nephrogenic Systemic Fibrosis / Nephrogenic Fibrosing Dermopathy

Treatment Options For Nephrogenic Systemic Fibrosis / Nephrogenic Fibrosing Dermopathy

Dialysis May Prevent Nephrogenic Systemic Fibrosis

Risk For Nephrogenic Systemic Fibrosis in Patients With Advanced Kidney Disease

Gadolinium Based MRI Contrast Agent Section

Magnevist MRI NSF

Gadolinium Based Contrast Agent - Magnevist

>> Magnevist and Nephrogenic Systemic Fibrosis

MultiHance MRI NSF

Gadolinium Based Contrast Agent – MultiHance

Gadolinium Based Contrast Agent - Omniscan

Gadolinium Based Contrast Agent - OptiMARK

Gadolinium Based Contrast Agent - ProHance

Omniscan Lawsuit

Omniscan MRI NSF

OptiMARK MRI NSF

Prohance MRI NSF

Related Websites & Recent Gadolinium Studies

5/23/07 - FDA Press Release

2/07/07 - Study Links Gadolinium treatment to NSF

1/25/07 - MRI Contrast Agent Linked to Rare Disease

1/15/07 - Dialysis to Prevent NSF After Gadolinium Treatment

Do I have a Gadolinium Lawsuit?

The Products Liability Litigation Group at our law firm is an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in Gadolinium lawsuits. We are handling individual litigation nationwide and currently accepting new Gadolinium side effect cases in all 50 states.

Attention Attorneys: We do not publish prior verdict/settlements. If you are an attorney and would like to refer us a case or for us to send you a profile of prior award judgments or average referral fees, please visit the attorney referral section of our website.

= Required Field